Toward realistic pharmaceutical evaluation: Challenges in 3D-printed organ chip of vascularized tissue with microcirculation

Ling Wang; Ziyan Qiu; Yingjie Liu; Fei Wang; Dichen Li

doi:10.1016/j.jpha.2025.101445

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2025 > Accepted Manu

Ling Wang, Ziyan Qiu, Yingjie Liu, Fei Wang, Dichen Li. Toward realistic pharmaceutical evaluation: Challenges in 3D-printed organ chip of vascularized tissue with microcirculation[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101445

Citation:

Ling Wang, Ziyan Qiu, Yingjie Liu, Fei Wang, Dichen Li. Toward realistic pharmaceutical evaluation: Challenges in 3D-printed organ chip of vascularized tissue with microcirculation[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101445

Citation:

Ling Wang, Ziyan Qiu, Yingjie Liu, Fei Wang, Dichen Li. Toward realistic pharmaceutical evaluation: Challenges in 3D-printed organ chip of vascularized tissue with microcirculation[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101445

PDF( 543 KB)

Toward realistic pharmaceutical evaluation: Challenges in 3D-printed organ chip of vascularized tissue with microcirculation

doi: 10.1016/j.jpha.2025.101445

Ling Wang^1,2,
Ziyan Qiu^1,2,
Yingjie Liu^1,2,
Fei Wang^1,2,
Dichen Li^{1,2
,
,}

1. State Key Laboratory for Manufacturing System Engineering, School of Mechanical Engineering, Xi'an Jiaotong University, 710054, Xi’an, China;
2. State Industry-Education Integration Center for Medical Innovations, Xi’an Jiaotong University, 710054, Xi’an, China

Funds:

The work was supported by the Program of the National Natural Science Foundation of China (Grant Nos.: 52435006, and 52275291), the Program for Innovation Team of Shaanxi Province (Grant No.: 2023-CX-TD-17), and the Fundamental Research Funds for the Central Universities.

Available Online: Sep. 05, 2025

Abstract

FullText(HTML)

References(10)

References

[1]	R. M. Plenge, Disciplined approach to drug discovery and early development, Sci. Transl. Med. 8 (2016) 349ps15-349ps15.
[2]	G. A. Van Norman, Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach?, JACC Basic Transl. Sci. 4 (2019) 845-854.
[3]	D. K. Brubaker, D. A. Lauffenburger, Translating preclinical models to humans, Science 367 (2020) 742-743.
[4]	H.R. 2565 – FDA Modernization Act of 2021 (117th Congress, 2021–2022). U.S. Congress Website.
[5]	U.S. Food and Drug Administration, Roadmap to reducing animal testing in preclinical safety studies (2025).
[6]	S. Ahadian, R. Civitarese, D. Bannerman, et al., Organ-on-a-chip platforms: a convergence of advanced materials, cells, and microscale technologies, Adv. Healthcare Mater. 7 (2018) 1700506.
[7]	L. Wang, S. Wang, Y. Liu, et al., Biofabrication of brain-like living tissue: structure to intelligence, Int. J. Extreme Manuf. 7 (2025) 032005.
[8]	L. Wang, L. Bai, S. Wang, et al., Biomimetic design and integrated biofabrication of an in vitro three dimensional multi scale multilayer cortical model, Mater. Today Bio 28 (2024) 101176.
[9]	S. Wang, L. Bai, X. Hu, et al., 3D bioprinting of neurovascular tissue modeling with collagen-based low-viscosity composites, Adv. Healthcare Mater. 12 (2023) e2300004.
[10]	J. Ma, X. Min, M. Wu, et al., The development of cerebral vasculature and related diseases, Scientia Sinica Vitae 54 (2024) 369-382.